공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

갱년기 안면홍조 치료 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Menopausal Hot Flashes Market - Growth, Trends, COVID-19 Impact, And Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 925361
페이지 정보 영문
가격
US $ 4,250 ₩ 4,793,000 PDF (Single User License)
US $ 4,750 ₩ 5,357,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,766,000 PDF (Site License)
US $ 7,500 ₩ 8,458,000 PDF (Corporate License)


갱년기 안면홍조 치료 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Menopausal Hot Flashes Market - Growth, Trends, COVID-19 Impact, And Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 갱년기 안면홍조(Menopausal Hot Flashes) 치료 시장은 2021-2026년간 3.4%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

세계의 갱년기 안면홍조 치료 시장을 조사했으며, 시장의 개요, 제품 유형·지역별 시장 규모의 추이와 예측, 시장 동향, 시장 성장요인 및 저해요인 분석, 시장 기회, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장요인
    • 갱년기 혈관운동증상의 발생률 상승
    • 치료를 위한 신약 개발의 기술 진보
  • 시장 억제요인
    • 호르몬 투여의 부작용
    • 제네릭 의약품의 가용성
  • Porter's Five Forces 분석
    • 신규 진출의 위협
    • 바이어의 교섭력
    • 공급업체의 교섭력
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제5장 시장 세분화

  • 제품별
    • 에스트로겐 온리 의약품
    • 프로게스틴 온리 의약품
    • 에스트로겐과 프로게스틴 병용약
    • 에스트로겐과 기타 의약품의 조합
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동·아프리카 지역
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Allergan Plc
    • Bayer AG
    • Novartis AG
    • Pfizer, Inc
    • Novo Nordisk Corporation
    • Hisamitsu Pharmaceutical Co., Inc
    • Merck & Co., Inc
    • Teva Pharmaceutical Industries Ltd

제7장 시장 기회 및 향후 전망

KSA 20.05.21

The menopausal hot flashes market is projected to register a CAGR of 3.4% during the forecast period.

The COVID-19 pandemic has been continuing to transform the growth of various markets, the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the outbreak of COVID-19 worldwide and lockdown situation across some countries have shown some challenges on the market studied, due to hold on services by the hospitals and clinics, in order to prevent the spread of COVID-19 virus and in fact, the tremendous pressure on the hospitals in providing services to COVID-19 patients is also one of the factors, which has been inhibiting the hospitals and clinics in providing women health services. According to the article published on the National Institute of Health 2020, United Nations Population Fund estimated that there is a decline in women's health services initially due to lockdown. However, as of now several countries have now eased restrictions which further create growth avenues in forcasted period.

The increasing incidence of menopausal hot flashes, increasing number of new drug approvals for the treatment and rising awareness regarding menopause health are the key driving factors in menopausal hot flashes market. Hot flashes are a sudden feeling of warmth, which is usually most intense over the chest, neck, and face. Hot flashes cause redness of the skin (called as flushing) and excessive sweating. Hot flashes generally occur due to menopause when menstrual periods become irregular and eventually stop. In fact, hot flashes are the most common symptom of the menopausal transition (which includes stages such as pre-menopause, perimenopause, and post-menopause). Hot flashes occurrence varies among women and can range from a few a week to several hours. Some of the symptoms during a hot flash are rapid heartbeat, flushed appearance with red, blotchy skin, perspiration, mostly on your upper body, a sudden feeling of warmth spreading through your upper body and face and so on. Hot flashes can vary in intensity and frequency. On average, symptoms of hot flashes persist for more than seven years or Sometimes in some women, it may be for more than 10 years. Hot flashes cause due to changes in reproductive hormones which becomes more sensitive to slight changes in body temperature. Factors such as smoking, obesity, ethnicity may increase risk in the development of hot flashes.

According to the study published in The Lancet Journal 2018, an estimated 1 billion women globally, will be older than 50 years, within the next 25 years and therefore likely to be reporting menopause or postmenopausal conditions. In addition, approximately 73% of postmenopausal women, experience hot flashes (vasomotor symptoms) and may result in fatigue, decreased cognitive function and sleep disturbances which lead to a reduction in their quality of life and an increased use of medical resources.

In addition, according to a 2019 study published in NCBI, it was stated that hot flashes are among the most common types of menopausal vasomotor symptoms (VMS), affecting up to 74% of perimenopausal women. Around 65% of women complain of hot flashes for more than two years, and 36% for more than five years. Thus, the rising incidences of menopausal vasomotor symptoms act as a major factor in the driving the growth of the menopausal hot flashes market

Other factors limiting the growth of this market are the side effects associated with hormonal products and availability of generic medicines.

Key Market Trends

Estrogen Segment is Expected to Hold a Major Market Share in the Menopausal Hot Flashes Market

The COVID-19 pandemic has affected the supply chain of pharmaceutical products. The restrictions on pharmaceutical manufacturing and export had affected many products sold in some countries, such as the United States, Europe, and other countries. Some of the drugs are manufactured in-house at the pharma companies, while other drugs of the company are manufactured with facilities in other countries, such as contract manufacturing services, which further impacted the supply chain of products.

Estrogen medicines help in boosting women's hormone levels and minimize symptoms of the menopausal transition, including hot flashes. Some of the USFDA-approved estradiol-containing products to treat hot flashes are Alora, Estraderm, Estrogel, Evamist, Vivelle, Climara, Divigel, and Estrace.

As per The International Menopause Society, women aged below 45 years who are postmenopausal have a 30% lower risk of breast cancer when compared to women who become premenopausal between 45-54 years are at greater risk of breast cancer. The estrogen-segment hold a significant market share in the menopausal hot flashes market and is anticipated to show a similar trend over the forecast period.

In additon Some of the benefits associated with estrogen medicines includes it helps in improving vaginal health, can help reduce symptoms of menopause, and may promote bone and heart health.

The Novartis AG company offers "Vivelle-DOT (estradiol transdermal system)" used in the treatment of moderate to severe vasomotor symptoms due to menopause and treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Furthermore, the Novo Nordisk Corporation company offers "Vagifem" 10 mcg vaginal tablet that treats changes in and around the vagina that occur after menopause and treats a combination of vaginal symptoms.

Hence, increasing incidence of menopausal hot flashes and technological advancements in the development of new drugs by innovative players in the market are the key driving factors in the estrogen segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The United States is the most COVID-19 affected country across the world. The supply chain of products was highly impacted in this country. Initially, there is a decline in demand for hot flashes products which has negatively impacted the overall market growth. However, as of now, the import-export restrictions have been reduced which is creating growth avenues in the forecasted period.

North America expected to hold a major market share in the global menopausal hot flashes market due to the increasing incidence of menopausal hot flashes, rising awareness regarding menopause health, and the presence of a larger percentage of older women in the overall population in this region. According to the North American Menopause Society, about 75% of North American women experience hot flashes during perimenopause, and approximately a quarter of them experience enough discomfort to seek relief from their clinicians. In addition, According to a 2020 study by Kimberly Peacock et al., published in NCBI, stated that in the United States, approximately 1.3 million women become menopausal each year, which begins between the ages of 51 and 52. In addition to the same source, approximately 5% of women experience early menopause between the ages of 40 and 45.

Moreover, favorable policies initiated by the government, such as Healthy People 2020, was established by the Department of Health and Human Services, which has a 10-year agenda to improve the health of all Americans is likely to drive market growth.

In addition the rising geriatric population in Canada and Mexico is also fueling the overall market demand. for instance according to United Nations Department of Economic and Social Affairs in Canada there are around 6,602 thousand people who are aged over 65 years in 2019 and the number is estimated to reach 9,317 thousand by 2030. In addition to the same source mentioned above in Mexico, there are around 9,462 thousand people who are aged over 65 years in 2019 and the number is estimated to reach 14,367 thousand by 2030. The prevalence of menopause is high in women geriatric population and thus boost the overall market growth.

Furthermore, technological advancements in the development of new drugs, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Menopausal Hot Flashes Market is fragmented competitive and consists of several major players. A large portion of the market share is taken up by small and mid-sized companies that produce generic treatment options. Some of the companies which are currently dominating the market are Abbvie inc (Allergan Plc), Bayer AG, Novartis AG, Pfizer, Inc, Novo Nordisk Corporation, Hisamitsu Pharmaceutical Co., Inc, Merck & Co., Inc, and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Menopausal Vasomotor Symptoms
    • 4.2.2 Technological Advancement in the Development of New Drugs for the Treatment
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Hormonal Products
    • 4.3.2 Availability of Generic Medicines
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Hormonal Treatment
      • 5.1.1.1 Estrogen
      • 5.1.1.2 Progesterone
      • 5.1.1.3 Estrogen-Progesterone Combination
    • 5.1.2 Non-hormonal Treatment
      • 5.1.2.1 Antidepressant
      • 5.1.2.2 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie inc (Allergan Plc)
    • 6.1.2 Bayer AG
    • 6.1.3 Novartis AG
    • 6.1.4 Pfizer, Inc
    • 6.1.5 Novo Nordisk Corporation
    • 6.1.6 Hisamitsu Pharmaceutical Co., Inc
    • 6.1.7 Merck & Co., Inc
    • 6.1.8 Teva Pharmaceutical Industries Ltd
    • 6.1.9 Agile Therapeutics
    • 6.1.10 Amgen Inc
    • 6.1.11 AstraZeneca plc
    • 6.1.12 Bristol-Myers Squibb Company
    • 6.1.13 Ferring BV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q